in the first trimester. We aimed to explore pregnancy outcomes in women with a positive PE screening test using the Fetal Medicine Foundation (FMF) algorithm. Methods: We conducted a prospective cohort study of Canadian pregnant women with singleton fetus recruited at 11-14 weeks. Lethal anomalies and medical termination of pregnancies were excluded. Maternal age, body mass index, methods of conception, personal history of PE, ethnicity, mean arterial blood pressure, PAPP-A, PlGF and mean uterine artery pulsatility index were submitted into the online FMF algorithm. Simple imputation was used for the treatment of missing values. Pregnancy outcomes, including PE, small for gestational age (SGA) <3rd centile and fetal death, were reported for women with a positive preterm PE screening test (≥1/70) and compared to women with a negative (<1/70) screening test. Results: We included 6067 participants, including 672 (11%) with a positive FMF screening test. The latter were at greater risk of PE (13.4% vs. 3.4%), preterm PE (3.7% vs. 0.3%), PE<34 weeks (1.3% vs. 0.09%), SGA<3rd centile (4.1% vs. 1.4%), preterm SGA<3rd centile (0.7% vs. 0.04%), fetal death (1.2% vs. 0.4%; p=0.004), miscarriage at 14-20 weeks (0.6% vs. 0.2%; p=0.04), or any of the above complications (16.8% vs. 5.0%) than women with negative screening test (all with p<0.0001, except if otherwise specified). Thirty (4.5%) women with a positive test developed one of the severe complications (preterm PE, preterm SGA, fetal death) compared to 31 (0.6%) women with a negative screening test (p<0.0001) after exclusion of miscarriages. Conclusions: Women with a first-trimester positive FMF preterm PE screening test are at high-risk of severe pregnancy complications that are preventable with low-dose aspirin in early pregnancy.
Objectives: Circulating angiogenic factors, e.g. sFlt-1 and PlGF, have a leading role in predicting pre-eclampsia mainly among women at high risk. We aimed to study the predictive value of serial sFlt-1/PlGF measurement in predicting the development of placental syndrome (PS) in women at high risk. Methods: We retrospectively studied data from 78 women with singleton pregnancies at high risk of PS based on previous obstetric or medical history, from the obstetrics and gynecology department, Maastricht UMC (MUMC + ), between January 2015 and February 2017. All women had serial measurement of sFlt-1 using the Kryptor platform (Thermo Fischer). We evaluated the absolute differences in serum concentrations (delta) of sFlt-1, PlGF and sFlt-1/PlGF ratio at different sampling intervals (12-30, 16-30 and 20-30 weeks) , as well as the relative change of each factor normalised to its concentration at 12. PS was defined as the development of any of the following: pre-eclampsia, IUGR, HELLP syndrome and placental abruption. Results: Ten out of 78 women developed PS (13%). There were no differences between the subgroup who developed PS vs those who did not, in absolute delta sFlt-1, PlGF, nor sFlt-1/PlGF ratio, at any time interval. However, women who developed PS, had a lower relative delta PlGF in the 12-30 weeks interval: 7. Objectives: Differences in the circulating antiangiogenic factor, soluble vascular endothelial growth factor receptor-1 (sFlt-1), and the proangiogenic placental growth factor (PlGF) seem to accurately predict pre-eclampsia (PE). The objective of this study was to investigate diagnostic accuracy of different cut-off values in preterm (≤36+6 WOG) and term PE (≥37+0 WOG). Methods: A prospective cohort study was performed at the University Hospital of Basel and Geneva from 1/2012 until 3/2015. Pregnant women with singleton pregnancies and high risk to develop PE or with symptoms were approached. Only blood samples on day of PE diagnosis were included and compared to a GA matched high risk control group (+/-4 days). Primary outcome was to verify the PE diagnosis using the recently proposed cut-off values for PE prediction (sFlt-1:PlGF ratio of ≥ 85 in < 34 weeks of gestation (WOG) ]). For the ratio, sensitivity and specificity of the proposed rule in cut-off values were 94% (95% confidence interval (CI), 80-99%) and 96% (95% CI, 87-100%). Equal results were achieved applying the calculated 95th quantile of the ratio, the 95th quantile of sFlt-1 and the 5th quantile of PlGF. In the term PE subset, 23 PE women and 35 controls were analysed (38 +6 WOG, IQR [37 +0 ; 41 +4 ]). For the ratio, sensitivity and specificity of the proposed rule in cut-off values were low with 30% (95% CI, 13-53%) and 97% (95% CI, 85-100%) as well as for the calculated 95th quantile and for the 5th quantile of PlGF. Best performance is achieved if the 90th quantile of sFlt-1 is used (78% (95% CI, 56-93%) and 89% (95% CI, 73-97%)).The reference GA dependent quantiles added no further benefit. Conclusions: In a high risk population, the 90th quantile of the single biomarker sFlt-1 seems to be superior to the ratio of sFlt-1:PlGF in the assessment of PE in term pregnant women. 
